Semler Scientific (OTC: SMLR) reported Q4 EPS of $0.17, $0.02 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $5.96 million versus the consensus estimate of $6.23 million.

"When disease processes are recognized earlier, preventive healthcare can be started sooner, thus providing a cost-efficient, practical means to achieve better patient management," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. "We believe that our QuantaFlo™ product allows our customers to help those under their care in just such a manner, which we believe is a contributing factor to our company's continued growth."

For earnings history and earnings-related data on Semler Scientific (SMLR) click here.